CNBC Television
@CNBCtelevision·3.4M subscribers·157.5K videos
ISIS Pharmaceuticals CEO Dr. Stanley Crooke | Mad Money
Posted
March 4, 2014
Views
1,569
Likes
8
Comments
1
Engagement
0.57%
March 4, 2014
1,569
8
1
0.57%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Episode Timeline
Every episode in order around the one you’re watching — click any card and the page flips straight to it.
7:15Now PlayingInnovative new drugs have helped Isis Pharmaceuticals more than triple in the past year. With two treatments entering the final phase of FDA approval, will 2014 be a breakout year for Isis or is the risk not worth the reward?
» Subscribe to CNBC
» Watch more Mad Money here
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Watch full episodes
Follow Mad Money on Twitter
Like Mad Money on Facebook
Follow Cramer on Twitter
Connect with CNBC News Online!
Get the latest news
Find CNBC News on Facebook
Follow CNBC News on Twitter
Follow CNBC News on Google+
Follow CNBC News on Instagram
ISIS Pharmaceuticals CEO Dr. Stanley Crooke | Mad Money | CNBC
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
